New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
UP AFTER EARNINGS: Royal Bank of Scotland (RBS), up 9%... Sequenom (SQNM), up 8.2%... Nutrisystem (NTRI), up 11.5%... American Axle (AXL), up 2.9%. ALSO HIGHER: Wynn Resorts (WYNN), up 4% after earnings, shares upgraded at Sterne Agee... Avanir (AVNR), up 3.7% after upgraded at Mizuho... RXi Pharmaceuticals (RXII), up 27.4% after announcing results from study of RXI-109... Intuitive Surgical (ISRG), up 4% after announcing accelerated share repurchase. DOWN AFTER EARNINGS: Chevron (CVX), down 1%... OpenTable (OPEN), down 3.4%... Actuate (BIRT), down 18.2%... SciQuest (SQI), down 20%... ServiceSource (SREV), down 15.2%. ALSO LOWER: Endocyte (ECYT), down 60% after announcing DSMB recommends vintafolide PROCEED trial be stopped. The drug is being developed in partnership with Merck (MRK)... Immunomedics (IMMU), down 16% after filing to sell $30M worth of common stock in a spot secondary offering... InvenSense (INVN), down 9.3% after downgraded at Needham following the company's Q4 earnings report... Blucora (BCOR), down 10% after earnings, downgrade at Craig-Hallum.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 24, 2015
05:29 EDTMRKMerck initiated with a Hold at Berenberg
Target $61.
November 23, 2015
16:42 EDTSQIDiscovery Group reports 5.3% stake in SciQuest
10:47 EDTISRGIntuitive Surgical CEO says 'probably not leading indicator' of total admissions
Subscribe for More Information
November 22, 2015
15:03 EDTMRKMerck reports multiple data sets from Keytruda combination studies
Subscribe for More Information
November 19, 2015
10:11 EDTINVNHigh option volume stocks
06:34 EDTMRKEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
08:18 EDTINVNRoth Capital to hold a conference
Roth Capital Tech Corporate Access Day to be held in New York on November 18.
08:11 EDTMRKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
07:01 EDTMRKThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.
November 17, 2015
18:34 EDTRBSU.S. pursuing criminal charges against JPMorgan, RBS executives, WSJ says
Subscribe for More Information
09:08 EDTINVNInvenSense enters distribution deals with Honestar, GH Development
Subscribe for More Information
08:04 EDTMRKMerck to present new KEYTRUDA findings at upcoming congresses
Merck announced that data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. In total, data from more than 30 abstracts will be presented at the Society for Melanoma Research 2015 Congress in San Francisco, Nov. 18 - 21; the 57th American Society of Hematology Annual Meeting in Orlando, Florida, Dec. 5 - 8; the San Antonio Breast Cancer Symposium, Dec. 8 - 12; and the European Society for Medical Oncology Asia 2015 Congress in Singapore, Dec. 18 - 21. By the end of 2015, data on the anti-tumor activity of KEYTRUDA will have been presented across more than 20 tumor types. "The field of immuno-oncology holds great potential across a broad spectrum of cancers," said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories. "Data for KEYTRUDA being presented at these scientific meetings include a first-time comparison to chemotherapy in advanced non-small cell lung cancer, novel combination data in advanced melanoma as well as first-time data in two additional tumor types, namely multiple myeloma and hormone receptor positive breast cancer, further demonstrating our deep commitment to advancing cancer treatment."
November 16, 2015
17:02 EDTAXL, CVXPoint72 added to lululemon position, subtracted from Netflix position
Subscribe for More Information
08:35 EDTMRKMerck to present Phase 2 hep C therapy data at The Liver Meeting
Subscribe for More Information
08:07 EDTAVNRConcert Pharmaceuticals achieves $2M milestone from Avanir
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the progression of the clinical development of AVP-786. The milestone is a result of Avanir initiating dosing of patients in a Phase 3 clinical trial with AVP-786 for the treatment of agitation in patients with Alzheimer's disease. The collaboration agreement between Concert and Avanir provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan (d-DM) compounds. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the third development milestone Concert has earned under this agreement.
08:05 EDTAVNRAvanir initiates Phase III trial of AVP-786
Avanir announced initiation of enrollment into a phase III clinical trial evaluating AVP-786 for the treatment of agitation in patients with Alzheimer's disease. This is the first of two placebo-controlled phase III trials in the company's TRIAD program. Avanir Pharmaceuticals recently received Fast Track designation from the FDA for the development of AVP-786 for this indication. The phase III studies are multicenter, randomized, double-blind, placebo-controlled trials that will evaluate two doses of AVP-786 versus placebo over a period of 12-weeks. Endpoints in these studies will include the Cohen Mansfield Agitation Inventory, the agitation/aggression domain of the Neuropsychiatry Inventory (NPI), other domains of the NPI, measures of global clinical change, and measures of caregiver burden and quality of life. Standard safety measurements will also be performed. TRIAD-1 is expected to enroll approximately 380 patients in 60 centers in the United States. TRIAD-2 is expected to enroll approximately 325 patients in 50 centers in the U.S. and will begin later in 2015. In addition to these two U.S. based trials, there will be additional global trials that will be conducted as part of the TRIAD program. Avanir has also initiated a phase II study to assess the efficacy, safety and tolerability of AVP-786 for the treatment of symptoms associated with residual schizophrenia. This study is expected to enroll approximately 120 patients in the U.S. Additionally, Avanir is currently enrolling patients in a phase II study of AVP-786 for the adjunctive treatment of major depressive disorder. This study began in 2014 and is expected to complete enrollment in 2015.
07:24 EDTMRKSalomon to hold a conference
Subscribe for More Information
06:51 EDTCVXBig energy firms saw 70% earnings dip for first nine months, WSJ says
Subscribe for More Information
November 15, 2015
15:19 EDTMRKMerck reports integrated analysis of six trials of elbasvir/grazoprevir
Subscribe for More Information
15:15 EDTMRKMerck reports Phase 3 data on elbasvir/grazoprevir in patients injecting drugs
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use